Clinical Trial Update: A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of Trifluridine/Tipiracil with Anlotinib as second-line treatment for recurrent and metastatic Esophageal squa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• trifluridine/tipiracil (trifluridine/tipiracil)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING